metformin or glp 1 Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus GLP M 1 | Glimpride

This has been such a great conversation

However, the precise mechanisms linking gut microbiota, GLP-1 secretion, and host metabolic regulation remain incompletely understood and warrant further investigation

If you're on weight loss medication, its essential to talk with your clinician before making any changes to your dose

One study with more than 300 participants saw a 15.8% decrease in body weight for semaglutide after 68 weeks.3 Another study saw a 12.4% decrease after 72 weeks.4 Averaging those two outcomes, someone weighing 200 pounds could reasonably expect to lose around 14% of their body weight after about 16 months

Grade, age, BMI and diabetes were key determinants of pCR in multivariate analysis [101]

UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price